CO2022004902A2 - Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer - Google Patents

Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer

Info

Publication number
CO2022004902A2
CO2022004902A2 CONC2022/0004902A CO2022004902A CO2022004902A2 CO 2022004902 A2 CO2022004902 A2 CO 2022004902A2 CO 2022004902 A CO2022004902 A CO 2022004902A CO 2022004902 A2 CO2022004902 A2 CO 2022004902A2
Authority
CO
Colombia
Prior art keywords
disease
alzheimer
beta
treatment
amyloid antibody
Prior art date
Application number
CONC2022/0004902A
Other languages
English (en)
Spanish (es)
Inventor
Haeberlein Samantha Budd
Ying Tian
Laura Nisenbaum
Raj Rajagovindan
Gersham Dent
John Beaver
Edward Plowey
Thierry Bussiere
Roger Nitsch
Original Assignee
Biogen Ma Inc
Neurimmune Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc, Neurimmune Ag filed Critical Biogen Ma Inc
Publication of CO2022004902A2 publication Critical patent/CO2022004902A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CONC2022/0004902A 2019-10-22 2022-04-19 Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer CO2022004902A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962924633P 2019-10-22 2019-10-22
PCT/US2020/056676 WO2021081101A1 (en) 2019-10-22 2020-10-21 Anti-beta-amyloid antibody for treating alzheimer's disease

Publications (1)

Publication Number Publication Date
CO2022004902A2 true CO2022004902A2 (es) 2022-07-08

Family

ID=73344157

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0004902A CO2022004902A2 (es) 2019-10-22 2022-04-19 Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer

Country Status (13)

Country Link
US (1) US20220372123A1 (cg-RX-API-DMAC10.html)
EP (1) EP4048695A1 (cg-RX-API-DMAC10.html)
JP (2) JP2022553329A (cg-RX-API-DMAC10.html)
KR (1) KR20220084095A (cg-RX-API-DMAC10.html)
CN (1) CN114599393A (cg-RX-API-DMAC10.html)
AU (1) AU2020371612A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022007595A2 (cg-RX-API-DMAC10.html)
CA (1) CA3158513A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022004902A2 (cg-RX-API-DMAC10.html)
IL (1) IL292363A (cg-RX-API-DMAC10.html)
JO (1) JOP20220092A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022004678A (cg-RX-API-DMAC10.html)
WO (1) WO2021081101A1 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
EP3746476A1 (en) 2018-01-31 2020-12-09 Alector LLC Anti-ms4a4a antibodies and methods of use thereof
EP3746484A4 (en) 2018-01-31 2021-11-17 Alector LLC ANTI-MS4A6A ANTIBODY AND METHOD OF USING THEREOF
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
TW202300517A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2023081194A2 (en) * 2021-11-03 2023-05-11 Biogen Ma Inc. Methods for treating alzheimer's disease
KR20240142535A (ko) * 2022-02-02 2024-09-30 에자이 알앤드디 매니지먼트 가부시키가이샤 P-tau181 수준을 사용한 치료 방법
WO2024086796A1 (en) * 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
EP4608432A4 (en) * 2022-10-25 2026-08-12 Inst For Basic Science Ibs EXTRACTION METHODS TO ENABLE CEREBRAL-SPINAL FLUID DRAINAGE
EP4455161A1 (en) 2023-04-24 2024-10-30 ONO Pharmaceutical Co., Ltd. Human-derived anti-collapsin response mediator protein 2 (crmp2) antibodies
WO2025059487A2 (en) 2023-09-15 2025-03-20 Othair Prothena Limited Cell penetrating agents and uses thereof
WO2025117721A1 (en) * 2023-11-27 2025-06-05 Massachusetts Institute Of Technology Reconstituted lipoprotein particles to rescue lipid defects in the alzheimer's brain

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033325T2 (en) 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
US9040045B2 (en) * 2007-05-14 2015-05-26 Medtronic, Inc. Methods and device to neutralize soluble toxic agents in the brain
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9221900B2 (en) * 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
EP3275461A1 (en) * 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
EP2928494A4 (en) * 2012-12-07 2016-11-02 Biogen Internat Neuroscience Gmbh METHOD FOR REDUCING AMYLOIDER PLAQUE OF BRAIN WITH ANTI-ASS ANTIBODIES
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
MX2018015022A (es) * 2016-06-07 2019-08-14 Biogen Int Neuroscience Gmbh Métodos para el tratamiento de la enfermedad de alzheimer.

Also Published As

Publication number Publication date
JP2022553329A (ja) 2022-12-22
EP4048695A1 (en) 2022-08-31
CN114599393A (zh) 2022-06-07
BR112022007595A2 (pt) 2022-08-23
US20220372123A1 (en) 2022-11-24
AU2020371612A1 (en) 2022-05-19
CA3158513A1 (en) 2021-04-29
IL292363A (en) 2022-06-01
JOP20220092A1 (ar) 2023-01-30
KR20220084095A (ko) 2022-06-21
MX2022004678A (es) 2022-08-15
WO2021081101A1 (en) 2021-04-29
JP2026012271A (ja) 2026-01-23

Similar Documents

Publication Publication Date Title
MX2022004678A (es) Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
MX2020001732A (es) Tratamiento de las afecciones del sistema nervioso central.
CO2019011349A2 (es) Anticuerpos anti-péptido beta amiloide n3pglu y sus usos
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
MX385045B (es) Anticuerpo monoclonal recombinante para usarse en el tratamiento de la enfermedad de alzheimer.
MX2018015022A (es) Métodos para el tratamiento de la enfermedad de alzheimer.
MX2021000538A (es) Uso de sobetirome en el tratamiento de enfermedades de mielinizacion.
MX2018008557A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos.
BR112019002730A2 (pt) acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
EA201892190A1 (ru) Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
AR101740A1 (es) Terapia de combinación y composiciones
BR112014010803A2 (pt) método de tratamento
AR119158A1 (es) Tratamientos de angioedema hereditario
CO2021008665A2 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
MX2020006284A (es) Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.
CL2021001389A1 (es) Formulaciones en cápsula
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
AR119159A1 (es) Tratamientos de angioedema
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
PE20171258A1 (es) Inhalador de polvo seco que comprende propionato de fluticasona y xinafoato de salmeterol